Biohit’s Chinese Joint Venture proceeding as planned

Biohit Oyj November 11, 2013 at 11 A.M. local time (EET)

The official Certificate of Approval required for the establishment of a Joint Venture with foreign investment in the People’s Republic of China has been received for the Joint Venture formed between Anhui Wisdom-win Investment Co, Ltd. and Biohit Oyj. The Joint Venture has been registered as Biohit Healthcare (Hefei) Co., Ltd., located in the city of Hefei in Anhui province, China.

The regulatory approvals regarding the start of the production are pending and are expected to be finalized during 2014.

Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve people’s quality of life by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit’s series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com